IBMX, Non-specific cAMP and cGMP inhibitor (ab120840)
Key features and details
- Non-specific cAMP and cGMP inhibitor
- CAS Number: 28822-58-4
- Purity: > 98%
- Soluble in DMSO to 75 mM and in ethanol to 50 mM
- Form / State: Solid
- Source: Synthetic
製品の概要
-
製品名
IBMX, Non-specific cAMP and cGMP inhibitor -
製品の詳細
Non-specific cAMP and cGMP inhibitor -
精製度
> 98% -
CAS 番号
28822-58-4 -
構造式
製品の特性
-
体系名
1-Methyl-3-(2-methylpropyl)-7H-purine-2,6-dione -
分子量
222.24 -
分子式
C10H14N4O2 -
PubChem 登録番号
3758 -
保存方法
Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
溶解性
Soluble in DMSO to 75 mM and in ethanol to 50 mM -
使用に関する注意
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES 線形表記
CC(C)CN1C2=C(C(=O)N(C1=O)C)NC=N2 -
由来
Synthetic
-
研究分野
画像
-
2D chemical structure image of ab120840, IBMX, Non-specific cAMP and cGMP inhibitor
-
1e7 3T3-L1 cells were treated for 15 minutes with 1 µM dexamethasone (ab120743) and 1 µg x mL-1 insulin (ab123768) with the addition of 50 µM forskolin (ab120058), 0.5 mM IBMX (ab120840) or 0.1 mM 8-CPT-cAMP (ab120424), extracted according to the protocol. Lysates were diluted 50-fold, and tested in duplicates (+/-SD).
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (1)
ab120840 は 1 報の論文で使用されています。
- Wang P et al. Disruption of adipocyte HIF-1α improves atherosclerosis through the inhibition of ceramide generation. Acta Pharm Sin B 12:1899-1912 (2022). PubMed: 35847503